Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 232

1.

Retrovirus insertion site analysis of LGL leukemia patient genomes.

Li W, Yang L, Harris RS, Lin L, Olson TL, Hamele CE, Feith DJ, Loughran TP Jr, Poss M.

BMC Med Genomics. 2019 Jun 17;12(1):88. doi: 10.1186/s12920-019-0549-9.

2.

The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia.

Annageldiyev C, Gowda K, Patel T, Bhattacharya P, Tan SF, Iyer S, Desai D, Dovat S, Feith DJ, Loughran TP Jr, Amin S, Claxton D, Sharma A.

Haematologica. 2019 May 23. pii: haematol.2018.212886. doi: 10.3324/haematol.2018.212886. [Epub ahead of print]

3.

Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen.

Morad SAF, MacDougall MR, Abdelmageed N, Kao LP, Feith DJ, Tan SF, Kester M, Loughran TP Jr, Wang HG, Cabot MC.

Exp Cell Res. 2019 Aug 15;381(2):256-264. doi: 10.1016/j.yexcr.2019.05.021. Epub 2019 May 18.

PMID:
31112736
4.

Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Tan SF, Dunton W, Liu X, Fox TE, Morad SAF, Desai D, Doi K, Conaway MR, Amin S, Claxton DF, Wang HG, Kester M, Cabot MC, Feith DJ, Loughran TP Jr.

J Lipid Res. 2019 Jun;60(6):1078-1086. doi: 10.1194/jlr.M091876. Epub 2019 Apr 8.

PMID:
30962310
5.

Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes.

Olson KC, Kulling Larkin PM, Signorelli R, Hamele CE, Olson TL, Conaway MR, Feith DJ, Loughran TP Jr.

Cytokine. 2018 Nov;111:551-562. doi: 10.1016/j.cyto.2018.09.016. Epub 2018 Nov 17.

PMID:
30455079
6.

IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability.

Wang TT, Yang J, Zhang Y, Zhang M, Dubois S, Conlon KC, Tagaya Y, Hamele CE, Dighe S, Olson TL, Feith DJ, Azimi N, Waldmann TA, Loughran TP Jr.

Leukemia. 2019 May;33(5):1243-1255. doi: 10.1038/s41375-018-0290-y. Epub 2018 Oct 23.

7.

Restoring the Long Noncoding RNA MEG3 Indicates a Potential Role for JAK-STAT Signaling in Chronic Myeloid Leukemia.

Olson TL, Loughran TP Jr.

EBioMedicine. 2018 Sep;35:24. doi: 10.1016/j.ebiom.2018.08.019. Epub 2018 Aug 24. No abstract available.

8.

TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia.

Yang J, LeBlanc FR, Dighe SA, Hamele CE, Olson TL, Feith DJ, Loughran TP Jr.

Blood. 2018 Jun 21;131(25):2803-2815. doi: 10.1182/blood-2017-09-808816. Epub 2018 Apr 26.

9.

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.

Dufva O, Kankainen M, Kelkka T, Sekiguchi N, Awad SA, Eldfors S, Yadav B, Kuusanmäki H, Malani D, Andersson EI, Pietarinen P, Saikko L, Kovanen PE, Ojala T, Lee DA, Loughran TP Jr, Nakazawa H, Suzumiya J, Suzuki R, Ko YH, Kim WS, Chuang SS, Aittokallio T, Chan WC, Ohshima K, Ishida F, Mustjoki S.

Nat Commun. 2018 Apr 19;9(1):1567. doi: 10.1038/s41467-018-03987-2.

10.

Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia.

Kulling PM, Olson KC, Hamele CE, Toro MF, Tan SF, Feith DJ, Loughran TP Jr.

PLoS One. 2018 Feb 23;13(2):e0193429. doi: 10.1371/journal.pone.0193429. eCollection 2018.

11.

STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia.

Doshi UA, Shaw J, Fox TE, Claxton DF, Loughran TP, Kester M.

Signal Transduct Target Ther. 2017 Oct 27;2:17051. doi: 10.1038/sigtrans.2017.51. eCollection 2017.

12.

Chronic neutropenia in LGL leukemia and rheumatoid arthritis.

Gazitt T, Loughran TP Jr.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):181-186. doi: 10.1182/asheducation-2017.1.181. Review.

13.

Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia.

Savola P, Brück O, Olson T, Kelkka T, Kauppi MJ, Kovanen PE, Kytölä S, Sokka-Isler T, Loughran TP, Leirisalo-Repo M, Mustjoki S.

Haematologica. 2018 Feb;103(2):304-312. doi: 10.3324/haematol.2017.175729. Epub 2017 Dec 7.

14.

SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models.

Hengst JA, Dick TE, Sharma A, Doi K, Hegde S, Tan SF, Geffert LM, Fox TE, Sharma AK, Desai D, Amin S, Kester M, Loughran TP, Paulson RF, Claxton DF, Wang HG, Yun JK.

Cancer Transl Med. 2017 Jul-Aug;3(4):109-121. doi: 10.4103/ctm.ctm_7_17. Epub 2017 Aug 14.

15.

Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation.

Kulling PM, Olson KC, Olson TL, Hamele CE, Carter KN, Feith DJ, Loughran TP Jr.

J Steroid Biochem Mol Biol. 2018 Mar;177:140-148. doi: 10.1016/j.jsbmb.2017.07.009. Epub 2017 Jul 20.

16.

The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.

Tan SF, Pearson JM, Feith DJ, Loughran TP Jr.

Expert Opin Ther Targets. 2017 Jun;21(6):583-590. doi: 10.1080/14728222.2017.1322065. Epub 2017 May 2. Review.

17.

Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability.

Salzberg AC, Harris-Becker A, Popova EY, Keasey N, Loughran TP, Claxton DF, Grigoryev SA.

PLoS One. 2017 Mar 16;12(3):e0173723. doi: 10.1371/journal.pone.0173723. eCollection 2017.

18.

Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer.

Morad SAF, Davis TS, MacDougall MR, Tan SF, Feith DJ, Desai DH, Amin SG, Kester M, Loughran TP Jr, Cabot MC.

Biochem Pharmacol. 2017 Apr 15;130:21-33. doi: 10.1016/j.bcp.2017.02.002. Epub 2017 Feb 9.

19.

LGL leukemia: from pathogenesis to treatment.

Lamy T, Moignet A, Loughran TP Jr.

Blood. 2017 Mar 2;129(9):1082-1094. doi: 10.1182/blood-2016-08-692590. Epub 2017 Jan 23. Review.

20.

Acid ceramidase is upregulated in AML and represents a novel therapeutic target.

Tan SF, Liu X, Fox TE, Barth BM, Sharma A, Turner SD, Awwad A, Dewey A, Doi K, Spitzer B, Shah MV, Morad SA, Desai D, Amin S, Zhu J, Liao J, Yun J, Kester M, Claxton DF, Wang HG, Cabot MC, Schuchman EH, Levine RL, Feith DJ, Loughran TP Jr.

Oncotarget. 2016 Dec 13;7(50):83208-83222. doi: 10.18632/oncotarget.13079.

21.

Vitamin D in hematological disorders and malignancies.

Kulling PM, Olson KC, Olson TL, Feith DJ, Loughran TP Jr.

Eur J Haematol. 2017 Mar;98(3):187-197. doi: 10.1111/ejh.12818. Epub 2016 Nov 21. Review.

22.

Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia.

Olson KC, Kulling PM, Olson TL, Tan SF, Rainbow RJ, Feith DJ, Loughran TP Jr.

Cancer Biol Ther. 2017 May 4;18(5):290-303. doi: 10.1080/15384047.2016.1235669. Epub 2016 Oct 7.

23.

High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia.

Andersson EI, Tanahashi T, Sekiguchi N, Gasparini VR, Bortoluzzi S, Kawakami T, Matsuda K, Mitsui T, Eldfors S, Bortoluzzi S, Coppe A, Binatti A, Lagström S, Ellonen P, Fukushima N, Nishina S, Senoo N, Sakai H, Nakazawa H, Kwong YL, Loughran TP, Maciejewski JP, Mustjoki S, Ishida F.

Blood. 2016 Nov 17;128(20):2465-2468. Epub 2016 Oct 3. No abstract available.

24.

MicroRNA-150 negatively regulates the function of CD4(+) T cells through AKT3/Bim signaling pathway.

Sang W, Sun C, Zhang C, Zhang D, Wang Y, Xu L, Zhang Z, Wei X, Pan B, Yan D, Zhu F, Yan Z, Cao J, Loughran TP Jr, Xu K.

Cell Immunol. 2016 Aug-Sep;306-307:35-40. doi: 10.1016/j.cellimm.2016.05.007. Epub 2016 May 30.

PMID:
27329362
25.

Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.

Morad SA, Ryan TE, Neufer PD, Zeczycki TN, Davis TS, MacDougall MR, Fox TE, Tan SF, Feith DJ, Loughran TP Jr, Kester M, Claxton DF, Barth BM, Deering TG, Cabot MC.

J Lipid Res. 2016 Jul;57(7):1231-42. doi: 10.1194/jlr.M067389. Epub 2016 May 2.

26.

Fludarabine, idarubicin, and cytarabine regimen together with TKI followed by haploidentical hematopoietic stem cell transplantation, a success for relapsed Ph+ acute lymphoblastic leukemia.

Sang W, Wang Y, Zhang C, Yan D, Niu M, Yang C, Liu X, Sun C, Zhang Z, Loughran TP Jr, Xu K.

Clin Case Rep. 2016 Mar 4;4(4):390-5. doi: 10.1002/ccr3.438. eCollection 2016 Apr.

27.

Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach.

Epner EM, Saroya BS, Hasanali ZS, Loughran TP Jr.

Exp Hematol. 2016 Mar;44(3):157-60. doi: 10.1016/j.exphem.2015.12.011. Epub 2016 Jan 21. Review.

PMID:
26802532
28.

Combinatorial interventions inhibit TGFβ-driven epithelial-to-mesenchymal transition and support hybrid cellular phenotypes.

Steinway SN, Zañudo JGT, Michel PJ, Feith DJ, Loughran TP, Albert R.

NPJ Syst Biol Appl. 2015 Nov 26;1:15014. doi: 10.1038/npjsba.2015.14. eCollection 2015.

29.

MiR-150 impairs inflammatory cytokine production by targeting ARRB-2 after blocking CD28/B7 costimulatory pathway.

Sang W, Wang Y, Zhang C, Zhang D, Sun C, Niu M, Zhang Z, Wei X, Pan B, Chen W, Yan D, Zeng L, Loughran TP Jr, Xu K.

Immunol Lett. 2016 Apr;172:1-10. doi: 10.1016/j.imlet.2015.11.001. Epub 2015 Nov 5.

30.

Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia.

Andersson E, Kuusanmäki H, Bortoluzzi S, Lagström S, Parsons A, Rajala H, van Adrichem A, Eldfors S, Olson T, Clemente MJ, Laasonen A, Ellonen P, Heckman C, Loughran TP, Maciejewski JP, Mustjoki S.

Leukemia. 2016 May;30(5):1204-8. doi: 10.1038/leu.2015.263. Epub 2015 Sep 30. No abstract available.

31.

Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.

LeBlanc FR, Liu X, Hengst J, Fox T, Calvert V, Petricoin EF 3rd, Yun J, Feith DJ, Loughran TP Jr.

Cancer Biol Ther. 2015;16(12):1830-40. doi: 10.1080/15384047.2015.1078949.

32.

MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN-γ production.

Sang W, Zhang C, Zhang D, Wang Y, Sun C, Niu M, Sun X, Zhou C, Zeng L, Pan B, Chen W, Yan D, Zhu F, Wu Q, Cao J, Zhao K, Chen C, Li Z, Li D, Loughran TP Jr, Xu K.

Am J Hematol. 2015 Nov;90(11):998-1007. doi: 10.1002/ajh.24136. Epub 2015 Oct 8.

33.

Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia.

Morad SA, Davis TS, Kester M, Loughran TP Jr, Cabot MC.

Leuk Res. 2015 Oct;39(10):1071-8. doi: 10.1016/j.leukres.2015.06.009. Epub 2015 Jul 2.

34.

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.

Hasanali ZS, Saroya BS, Stuart A, Shimko S, Evans J, Vinod Shah M, Sharma K, Leshchenko VV, Parekh S, Loughran TP Jr, Epner EM.

Sci Transl Med. 2015 Jun 24;7(293):293ra102. doi: 10.1126/scitranslmed.aaa5079.

35.

Inference of Network Dynamics and Metabolic Interactions in the Gut Microbiome.

Steinway SN, Biggs MB, Loughran TP Jr, Papin JA, Albert R.

PLoS Comput Biol. 2015 Jun 23;11(5):e1004338. doi: 10.1371/journal.pcbi.1004338. eCollection 2015 May.

36.

Identification of indels in next-generation sequencing data.

Ratan A, Olson TL, Loughran TP Jr, Miller W.

BMC Bioinformatics. 2015 Feb 13;16:42. doi: 10.1186/s12859-015-0483-6.

37.

Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics.

Morad SA, Tan SF, Feith DJ, Kester M, Claxton DF, Loughran TP Jr, Barth BM, Fox TE, Cabot MC.

Biochim Biophys Acta. 2015 Jul;1851(7):919-28. doi: 10.1016/j.bbalip.2015.03.001. Epub 2015 Mar 10.

38.

Emergence of a STAT3 mutated NK clone in LGL leukemia.

Yan Y, Olson TL, Nyland SB, Feith DJ, Loughran TP Jr.

Leuk Res Rep. 2014 Dec 16;4(1):4-7. doi: 10.1016/j.lrr.2014.12.001. eCollection 2015.

39.

The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.

Dick TE, Hengst JA, Fox TE, Colledge AL, Kale VP, Sung SS, Sharma A, Amin S, Loughran TP Jr, Kester M, Wang HG, Yun JK.

J Pharmacol Exp Ther. 2015 Mar;352(3):494-508. doi: 10.1124/jpet.114.219659. Epub 2015 Jan 6.

40.

Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.

Doi K, Gowda K, Liu Q, Lin JM, Sung SS, Dower C, Claxton D, Loughran TP Jr, Amin S, Wang HG.

Cancer Biol Ther. 2014;15(12):1688-99. doi: 10.4161/15384047.2014.972799.

41.

Acquired inhibitors to factor VIII and fibrinogen in the setting of T-cell large granular lymphocyte leukemia: a case report and review of the literature.

Murphy PW, Brett LK, Verla-Tebit E, Macik BG, Loughran TP Jr.

Blood Coagul Fibrinolysis. 2015 Mar;26(2):211-3. doi: 10.1097/MBC.0000000000000209. Review.

PMID:
25396761
42.

Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.

Hasanali ZS, Epner EM, Feith DJ, Loughran TP Jr, Sample CE.

Mol Cancer Ther. 2014 Dec;13(12):2784-92. doi: 10.1158/1535-7163.MCT-14-0593. Epub 2014 Oct 15.

43.

Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998).

Loughran TP Jr, Zickl L, Olson TL, Wang V, Zhang D, Rajala HL, Hasanali Z, Bennett JM, Lazarus HM, Litzow MR, Evens AM, Mustjoki S, Tallman MS.

Leukemia. 2015 Apr;29(4):886-94. doi: 10.1038/leu.2014.298. Epub 2014 Sep 13.

44.

Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.

Sun X, Hasanali ZS, Chen A, Zhang D, Liu X, Wang HG, Feith DJ, Loughran TP Jr, Xu K.

Br J Haematol. 2015 Feb;168(3):371-83. doi: 10.1111/bjh.13143. Epub 2014 Oct 4.

45.

The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia.

Rajala HL, Olson T, Clemente MJ, Lagström S, Ellonen P, Lundan T, Hamm DE, Zaman SA, Lopez Marti JM, Andersson EI, Jerez A, Porkka K, Maciejewski JP, Loughran TP, Mustjoki S.

Haematologica. 2015 Jan;100(1):91-9. doi: 10.3324/haematol.2014.113142. Epub 2014 Oct 3.

46.

Network modeling of TGFβ signaling in hepatocellular carcinoma epithelial-to-mesenchymal transition reveals joint sonic hedgehog and Wnt pathway activation.

Steinway SN, Zañudo JG, Ding W, Rountree CB, Feith DJ, Loughran TP Jr, Albert R.

Cancer Res. 2014 Nov 1;74(21):5963-77. doi: 10.1158/0008-5472.CAN-14-0225. Epub 2014 Sep 4.

47.

Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation.

Barth BM, Keasey NR, Wang X, Shanmugavelandy SS, Rampal R, Hricik T, Cabot MC, Kester M, Wang HG, Shultz LD, Tallman MS, Levine RL, Loughran TP Jr, Claxton DF.

J Leuk (Los Angel). 2014 Sep;2(3). pii: 146. doi: 10.4172/2329-6917.1000146. Epub 2014 Jul 25.

48.

Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.

Cheng J, Talamo G, Malysz J, Ochmann M, Lamy T, Loughran TP Jr.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e169-72. doi: 10.1016/j.clml.2014.04.001. Epub 2014 Jun 12. No abstract available.

PMID:
25037886
49.

Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression.

Doi K, Liu Q, Gowda K, Barth BM, Claxton D, Amin S, Loughran TP Jr, Wang HG.

Cancer Biol Ther. 2014 Aug;15(8):1077-86. doi: 10.4161/cbt.29186. Epub 2014 May 19.

50.

The pathogenesis and treatment of large granular lymphocyte leukemia.

Steinway SN, LeBlanc F, Loughran TP Jr.

Blood Rev. 2014 May;28(3):87-94. doi: 10.1016/j.blre.2014.02.001. Epub 2014 Mar 7. Review.

Supplemental Content

Loading ...
Support Center